FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2747415234> ?p ?o ?g. }

• W2747415234 endingPage "120" @default.
• W2747415234 startingPage "86" @default.
• W2747415234 abstract "As of May 1, 2017, 74 antibody-based molecules have been approved by a regulatory authority in a major market. Additionally, there are 70 and 575 antibody-based molecules in phase III and phase I/II clinical trials, respectively. These total 719 antibody-based clinical stage molecules include 493 naked IgGs, 87 antibody-drug conjugates, 61 bispecific antibodies, 37 total Fc fusion proteins, 17 radioimmunoglobulins, 13 antibody fragments, and 11 immunocytokines. New uses for these antibodies are being discovered each year. For oncology, many of the exciting new approaches involve antibody modulation of T-cells. There are over 80 antibodies in clinical trials targeting T cell checkpoints, 26 T-cell-redirected bispecific antibodies, and 145 chimeric antigen receptor (CAR) cell-based candidates (all currently in phase I or II clinical trials), totaling more than 250 T cell interacting clinical stage antibody-based candidates. Finally, significant progress has been made recently on routes of delivery, including delivery of proteins across the blood-brain barrier, oral delivery to the gut, delivery to the cellular cytosol, and gene- and viral-based delivery of antibodies. Thus, there are currently at least 864 antibody-based clinical stage molecules or cells, with incredible diversity in how they are constructed and what activities they impart. These are followed by a next wave of novel molecules, approaches, and new methods and routes of delivery, demonstrating that the field of antibody-based biologics is very innovative and diverse in its approaches to fulfill their promise to treat unmet medical needs." @default.
• W2747415234 created "2017-08-31" @default.
• W2747415234 creator A5044774669 @default.
• W2747415234 date "2017-08-18" @default.
• W2747415234 modified "2023-10-06" @default.
• W2747415234 title "Current progress in innovative engineered antibodies" @default.
• W2747415234 cites W1266258446 @default.
• W2747415234 cites W1485730287 @default.
• W2747415234 cites W1492340933 @default.
• W2747415234 cites W1510837654 @default.
• W2747415234 cites W1518819083 @default.
• W2747415234 cites W1519582890 @default.
• W2747415234 cites W1529809181 @default.
• W2747415234 cites W1554896172 @default.
• W2747415234 cites W1571991353 @default.
• W2747415234 cites W1589766395 @default.
• W2747415234 cites W1604141497 @default.
• W2747415234 cites W1670498114 @default.
• W2747415234 cites W1737140009 @default.
• W2747415234 cites W1794874335 @default.
• W2747415234 cites W1855086894 @default.
• W2747415234 cites W1902650446 @default.
• W2747415234 cites W1943878720 @default.
• W2747415234 cites W1948401147 @default.
• W2747415234 cites W1966286047 @default.
• W2747415234 cites W1971883527 @default.
• W2747415234 cites W1972089838 @default.
• W2747415234 cites W1972193434 @default.
• W2747415234 cites W1973356354 @default.
• W2747415234 cites W1975094254 @default.
• W2747415234 cites W1979162895 @default.
• W2747415234 cites W1981730803 @default.
• W2747415234 cites W1982236072 @default.
• W2747415234 cites W1983494459 @default.
• W2747415234 cites W1986723482 @default.
• W2747415234 cites W1987871186 @default.
• W2747415234 cites W1989465964 @default.
• W2747415234 cites W1989485300 @default.
• W2747415234 cites W1991001030 @default.
• W2747415234 cites W1991987701 @default.
• W2747415234 cites W1992375147 @default.
• W2747415234 cites W1992376269 @default.
• W2747415234 cites W1992441329 @default.
• W2747415234 cites W1993639035 @default.
• W2747415234 cites W1995374080 @default.
• W2747415234 cites W1996045402 @default.
• W2747415234 cites W1996539011 @default.
• W2747415234 cites W1996820981 @default.
• W2747415234 cites W1997703904 @default.
• W2747415234 cites W1999146917 @default.
• W2747415234 cites W2001483547 @default.
• W2747415234 cites W2004265876 @default.
• W2747415234 cites W2009030875 @default.
• W2747415234 cites W2009179035 @default.
• W2747415234 cites W2011219467 @default.
• W2747415234 cites W2011766387 @default.
• W2747415234 cites W2011982742 @default.
• W2747415234 cites W2013973130 @default.
• W2747415234 cites W2017665745 @default.
• W2747415234 cites W2017668300 @default.
• W2747415234 cites W2021855052 @default.
• W2747415234 cites W2021865808 @default.
• W2747415234 cites W2022996599 @default.
• W2747415234 cites W2023202529 @default.
• W2747415234 cites W2025061302 @default.
• W2747415234 cites W2025779348 @default.
• W2747415234 cites W2028460943 @default.
• W2747415234 cites W2029850226 @default.
• W2747415234 cites W2030621571 @default.
• W2747415234 cites W2031855795 @default.
• W2747415234 cites W2033439473 @default.
• W2747415234 cites W2042411936 @default.
• W2747415234 cites W2042858467 @default.
• W2747415234 cites W2050557902 @default.
• W2747415234 cites W2051118090 @default.
• W2747415234 cites W2052150715 @default.
• W2747415234 cites W2054616684 @default.
• W2747415234 cites W2055338996 @default.
• W2747415234 cites W2055342376 @default.
• W2747415234 cites W2056362227 @default.
• W2747415234 cites W2057936669 @default.
• W2747415234 cites W2060609324 @default.
• W2747415234 cites W2066650336 @default.
• W2747415234 cites W2068173904 @default.
• W2747415234 cites W2068540171 @default.
• W2747415234 cites W2071843728 @default.
• W2747415234 cites W2073227280 @default.
• W2747415234 cites W2074348188 @default.
• W2747415234 cites W2074969682 @default.
• W2747415234 cites W2075097399 @default.
• W2747415234 cites W2076096560 @default.
• W2747415234 cites W2076347516 @default.
• W2747415234 cites W2078341282 @default.
• W2747415234 cites W2078607441 @default.
• W2747415234 cites W2081213281 @default.
• W2747415234 cites W2083435401 @default.
• W2747415234 cites W2086071777 @default.
• W2747415234 cites W2086146164 @default.

• next